Professor, Internal Medicine, Wayne State University School of Medicine
Hematology
Dr. Lois J. Ayash, MD
|
|
Give Review
Doctor Lois J. Ayash, MD practices Hematology. She studied medicine at University of Massachusetts Medical School. University of Massachusetts Medical School has a rank of 49 in research and a 12 in primary care Doctor Lois J. Ayash, MD is also a published doctor. She has 66 publication published. The most recent publication is: Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. She accepts Medicare payments and is registered with Medicare.gov.
Publications
- Targeting Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.
- Low blood lymphocyte count at 30 days post transplant predicts worse Acute GVHD and survival but not relapse in a large retrospective cohort.
- Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease.
- Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.
- Successful hematopoietic stem Cell collection in patients who fail initial plerixafor mobilization for autologous stem Cell transplant.
- High Incidence of Severe aGVHD with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplant Patients.
- Evaluating the effects of lenalidomide induction therapy on peripheral stem Cells collection in patients undergoing autologous stem Cell transplant for multiple myeloma.
- Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem Cells and incidence of secondary myelodysplastic syndrome/AML.
- A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple M...
- Anti-Thymocyte Globulin (Thymoglobulin), Tacrolimus, and Sirolimus as Acute Graft-versus-Host Disease Prophylaxis for Unrelated Hematopoietic Stem Cell Transplantation.
- Melphalan 180 mg/m(2) can be Safely Administered as Conditioning Regimen prior to an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Crea...
- Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk Acute myelogenous leukemia.
- Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's Disease.
- A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
- A perspective on dose-intensive therapy with autologous bone marrow transplantation for solid tumors.
- Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.
- Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response.
- Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast Cancer: a feasibility study.
- Hepatic venoocclusive Disease in autologous bone marrow transplantation of solid tumors and lymphomas.
- High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast Cancer.
- High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem Cell support: safety and future directions.
- Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation.
- High-dose chemotherapy with autologous stem cell support for breast Cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
- A preclinical model for sequential high-dose chemotherapy.
- Analysis of 4-hydroxycyclophosphamide in human blood.
- Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast Cancer.
- Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem Cell support.
- Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast Cancer: no improvement in progression-free survival by the sequence of high-...
- Antitumor efficacy and pharmacokinetic Analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
- Kinetics of peripheral blood mononuclear Cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic prog...
- Dose escalation of the hypoxic Cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem Cell support.
- High-dose multimodality therapy with autologous stem-cell support for stage IIIB Breast carcinoma.
- Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with Chronic graft-versus-host disease.
- Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem Cell transplantation.
- Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular Cancer: the University of Michigan experience and literatur...
- Clinical protocol. Purging of autologous stem cell sources with bcl-x(s) adenovirus for women undergoing high-dose chemotherapy for stage IV Breast carcinoma.
- Chronic graft-versus-host disease: clinical manifestation and therapy.
- Allogeneic stem cell transplantation reduces Disease progression compared to autologous transplantation in patients with multiple myeloma.
- A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast Cancer.
- High-dose chemotherapy and autologous stem-cell transplantation for ovarian Cancer: an autologous blood and marrow transplant registry report.
- Dose-intensive therapy for limited-stage small-cell lung Cancer: long-term outcome.
- High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's Disease: a prognostic model for treatment outcomes.
- Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast Cancer patients.
- Intensive combined modality therapy for limited-stage small-cell lung Cancer.
- Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's Lymphoma with cyclophosphamide, carmustine, and etop...
- High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung Cancer.
- The collection and evaluation of peripheral blood progenitor Cells sufficient for repetitive cycles of high-dose chemotherapy support.
- High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast Cancer responding to standard-dose therap...
- The use of G-CSF or GM-CSF mobilized peripheral blood progenitor Cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose c...
- High-dose thiotepa alone and in combination regimens with bone marrow support.
- Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an Analysis of four chemotherapy regimens.
- Mobilization of peripheral blood progenitor Cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensif...
- Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP Cells.
- A phase I trial of continuous-infusion cyclophosphamide in refractory Cancer patients.
- A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast Cancer responding to ...
- GM-CSF potentiated peripheral blood progenitor Cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols.
- Large pericardial effusion as a complication in adults undergoing SCT.
- Tacrolimus as monotherapy or combined with minidose methotrexate for Graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation:...
- West Nile virus encephalitis causing fatal CNS toxicity after hematopoietic stem Cell transplantation.
- Nephrotic syndrome associated with Chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
- Pilot trial on the use of etanercept and methylprednisolone as primary treatment for Acute graft-versus-host disease.
- Treatment of Chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody.
- Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays Acute graft-versus-host disease but does not improve outcome for advanced hematol...
- Long term follow-up of allogeneic stem Cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide.
- Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem Cell transplantation.
Schools
University Of Massachusetts Medical School
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
SUNY Upstate Medical University -
University of Massachusetts Medical School
Hospital
-
DMC - Detroit Receiving Hospital -
DMC Harper University Hospital
Drug Facts
| NPI NUMBER | 1699713982 | |
| NPPES Provider LastName | AYASH | |
| NPPES Provider FirstName | LOIS | |
| NPPES Provider ZIPCode | 482012013 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 271.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699713982 |
| Last Name Of The Provider | AYASH |
| First Name Of The Provider | LOIS |
| View All |
Similar Doctors
|
|
Dr. Anthony F. Shields, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paul S. Swerdlow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph P. Uberti, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Divaya Bhutani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Minsig Choi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ben Yan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ira S. Wollner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hemchandra Mahaseth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
George Yaghmour |